NEW YORK, NY / ACCESS Newswire / September 9, 2025 / If you suffered a loss on your Lockheed Martin Corporation (NYSE:LMT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/lockheed-martin-corporation-lawsuit-submission-form?prid=166241&wire=1&utm_campaign=27 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or […]

NEW YORK, NY / ACCESS Newswire / September 9, 2025 / If you suffered a loss on your Lineage, Inc. (NASDAQ:LINE) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/lineage-inc-lawsuit-submission-form?prid=166240&wire=1&utm_campaign=6 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call

NEW YORK, NY / ACCESS Newswire / September 9, 2025 / If you suffered a loss on your C3.ai, Inc. (NYSE:AI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/c3-ai-inc-lawsuit-submission-form?prid=166239&wire=1&utm_campaign=25 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call

Pomerantz LLP is investigating claims on behalf of investors of PACS Group, Inc. ("PACS" or the "Company") (NYSE:PACS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether PACS and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click

NEW YORK CITY, NY / ACCESS Newswire / September 9, 2025 / WHY: New York, N.Y., September 9, 2025. Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Soleno Therapeutics, Inc. (NASDAQ:SLNO) resulting from allegations that Soleno Therapeutics may have issued materially misleading

(AUST:TLX.AX),(NasdaqGM:TLX), MELBOURNE, Australia and INDIANAPOLIS, Sept. 10, 2025 (GLOBE NEWSWIRE) — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces it has dosed the first patient in a Phase 3 clinical trial aimed at expanding the indications for Illuccix(R) and Gozellix(R) (kits for the preparation of gallium-68 (68Ga) gozetotide injection) to include prostate cancer

Telix Doses First Patient in Phase 3 BiPASS Trial: PSMA-PET Imaging for Prostate Cancer Diagnosis GlobeNewswire September 09, 2025 MELBOURNE, Australia and INDIANAPOLIS, Sept. 10, 2025 (GLOBE NEWSWIRE) — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces it has dosed the first patient in a Phase 3 clinical trial aimed at expanding the

NEW YORK, NY / ACCESS Newswire / September 9, 2025 / If you suffered a loss on your KinderCare Learning Companies, Inc. (NYSE:KLC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/kindercare-learning-companies-inc-lawsuit-submission-form?prid=166238&wire=1&utm_campaign=6 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com

(NYSE:ANRO), NEW YORK, Sept. 09, 2025 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Alto Neuroscience, Inc. (NYSE: ANRO): (i) pursuant and/or traceable to Alto's initial public offering conducted on or about February 2, 2024 (the “IPO”); and/or (ii) securities between February 2, 2024

ANRO IMPORTANT DEADLINE: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Alto Neuroscience, Inc. Investors to Secure Counsel Before Important September 19 Deadline in Securities Class Action – ANRO GlobeNewswire September 09, 2025 NEW YORK, Sept. 09, 2025 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock